Next on the list is French mega pharmaceutical company Sanofi (NYSE:SNY).
Sanofi has its hands in just about everything, though it is particularly strong in its diabetes and cancer drugs and in treatments for heart disease and kidney disease. The company also has a presence in the veterinary pharmaceutical market.
Sanofi’s stock more or less tracked its Big Pharma peers through early May of this year before selling off sharply along with most European shares. The stock has rallied hard, however, and is now ahead of the broader iShares Health Care ETF (NYSE:IYH).
Sanofi trades for 11.5 times expected 2013 earnings and yields 3.9%.